Re-evaluation Note REV2025-01, Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2025-2030
Pest Management Regulatory Agency
15 July 2025
ISSN: 1925-0649 (PDF version)
Catalogue number: H113-5/2025-1E-PDF (PDF version)
Table of contents
- Background
- Work plan development
- Part A: Special reviews
- Part B: Re-evaluations and standalone quantitative cumulative health risk assessment
- Part C: Re-evaluations – Early stage of re-evaluation process
- Part D: Re-evaluation initiations between 1 April 2025 and 31 March 2030
Background
The purpose of this document is to inform registrants, pesticide regulatory officials and the Canadian public of the re-evaluation and special review work (in other words, the post-market reviews) planned by Health Canada's Pest Management Regulatory Agency (PMRA) for the next five fiscal years from 1 April 2025 to 31 March 2030. This document presents updates to the information last published in Re-evaluation Note REV2024-01, Pest Management Regulatory Agency Re-evaluation and Special Review Work Plan 2024-2029.
Health Canada regulates pesticides in Canada, with the primary objective of protecting the health of Canadians and the environment. A pesticide product may only be sold or used in Canada if it has been registered or otherwise authorized under the authority of the Pest Control Products Act. Health Canada uses a rigorous science-based risk assessment approach to ensure that the product meets health and environmental protection standards and has value.
As part of the post-market program, registered pesticides are re-evaluated on a cyclical basis to determine their continued acceptability. Pesticides may also be re-evaluated as a result of changes in the information required or the procedures used by Health Canada to determine that the pesticide meets current health, environment and value standards. The re-evaluation process is described in Regulatory Directive DIR2016-04, Management of Pesticides Re-evaluation Policy. In addition, a special review may be initiated at any time to address the identified aspect(s) of concern, and a special review is triggered only under certain circumstances. Special reviews differ from re-evaluations in that a special review is intended to examine only specific aspects of a pesticide. Additional information on special reviews can be found in the PMRA Guidance Document, Approach to Special Reviews of Pesticides.
As required under the Pest Control Products Act, Health Canada publishes all post-market proposed decisions for public consultation. Following consultation, comments and information submitted by the public and other stakeholders are considered before Health Canada issues a final decision. Stakeholders are encouraged to stay informed of upcoming consultations and decisions for pesticides by visiting the Pesticides and pest management section of Canada.ca.
This work plan includes the target dates for the proposed and final decisions to be published from 1 April 2025 and the status of all open re-evaluations and special reviews. In addition, new re-evaluations expected to be initiated from 1 April 2025 to 31 March 2030 are included for improved transparency for registrants and stakeholders.
This five-year work plan may change in response to workload and emerging issues that require priority action. During the course of the year, interested stakeholders can monitor the PMRA's Public Registry to view the announcement of new re-evaluations and special reviews, as well as other documents relevant to specific post-market reviews.
Work plan development
The re-evaluation and special reviews of several actives included in last year's plan (REV2024-01) have been carried over to this fiscal year due to the complex nature of the re-evaluations and the need to review large volumes of data and extensive use patterns. Resources were also focused on other priorities including an increased number of pre-market notices of objection and special review initiations. The number of re-evaluation initiations required as per the 15-year legislative requirement continues to be high and, given the current resource capacity considerations, the backlog is growing.
The PMRA's Continuous Oversight Model and Proportional Effort Framework will support operations and render them more efficient to ensure that the PMRA responds to emerging risks in a more timely manner and that the limited scientific resources are focused on issues that matter most. The PMRA consulted on the Proposed Continuous Oversight Policy (PRO2024-01) in 2024. Over the course of the year, the PMRA plans to publish the policy on Continuous Oversight and begin implementing it. Future implementation of the proportional effort policy following consultation will enable the PMRA to better focus review efforts to increase overall protection and make progress to eliminate the re-evaluation backlog. Finally, Health Canada will seek independent scientific advice on post-market reviews through the Science Advisory Committee, when necessary, to better inform its evidence-based decisions.
The following Tables outline the target publication dates for the proposed and final decisions of special reviews and re-evaluations established based on the currently available resources. In addition, next milestone target dates for the three standalone quantitative cumulative health risk assessments initiated are also included.
Part A: Special reviews
Special reviews are very focused and examine only specific aspects of a pesticide as outlined in PMRA Guidance Document, Approach to Special Reviews of Pesticides. While the aspect of concerns for each special review is included in the special review announcement available in the Public Registry, they are captured in the table below for easy access.
| Active ingredient name | Aspect of concerns | Target datePart A Footnote 1 |
|---|---|---|
| Proposed special review decision (PSRD) – For consultation | ||
| 1 April 2025 to 31 March 2026 | ||
Dicamba
|
Environment Risk to non-target terrestrial plants from the use of dicamba products (Over-the-Top (OTT) and non-OTT uses). |
September 2025 |
| Novaluron | Human health Potential dietary risks (food and water) from exposure to novaluron |
October 2025 |
| 1 April 2026 to 31 March 2027 | ||
Hydantoins
|
Human health Potential occupational inhalation risk for workers handling halohydantoin products formulated as granules. Potential residential postapplication cancer risk from incidental oral exposure to bromate in outdoor swimming pools treated with bromine-based halohydantoins and in swimming pools, spas and hot tubs in combination with electrolysis, ozonation or UV devices. |
Q1 (2026-27) |
MCPA
|
Human health Potential inhalation occupational (mixing/loading/applying) and residential risk from the use of MCPA. |
Q1 (2026-27) |
| Ethalfluralin | Human health Potential cancer risks from occupational exposure to ethalfluralin for:
|
Q2 (2026-27) |
| Propiconazole | Human health Potential exposure to propiconazole's transformation products (NOA436613, SYN547889, and CGA91305) in groundwater (drinking water). EnvironmentPotential reproductive risk to fish |
Q2 (2026-27) |
| Glufosinate ammonium | Human health Potential reproductive toxicity (including developmental toxicity); Potential occupational health risk; and Potential bystander risk. |
Q4 (2026-27) |
| 1 April 2027 to 31 March 2028 | ||
| Ethofumesate | Human health Potential risk from exposure to ethofumesate and transformation products NC 8493, NC 9607, and NC 20645 in drinking water; and Environment Potential risk to terrestrial and aquatic plants. |
Q1 (2027-28) |
| Thiacloprid | Human health Potential exposure to thiacloprid's transformation products M30, M34, and M46 in groundwater (drinking water) |
Q2 (2027-28) |
| Chlorpropham | Human health Dietary (food only) risk from exposure to chlorpropham and 3-chloroaniline residues. |
Q3 (2027-28) |
| Desmedipham | All products discontinued. Special review closed. | N/A |
| Final special review decision (SRD) | Target dateFootnote 1 | |
| 1 April 2025 to 31 March 2026 | ||
| Methyl bromide | Human health Potential for risk from occupational exposure. Potential for risk to bystanders. |
June 2025 |
| Chlorothalonil | Human health
Environment
|
October 2025 |
| Pydiflumetofen | Human health Potential occupational inhalation risk |
December 2025 |
| 1 April 2026 to 31 March 2027 | ||
| Atrazine | Human health and environment Potential changes to toxicology endpoint(s) used for previous human health and environmental risk assessments.
|
Q2 (2026-27) |
| 1 April 2027 to 31 March 2028 | ||
| Iodocarb (3-iodo-2-propynyl butyl carbamate) | Human health Potential dermal and inhalation risks of concern for secondary workers (machinists) exposed to iodocarb-treated metalworking fluids (MWF). Potential dermal and inhalation risks of concern for mixers/loaders treating MWF with iodocarb. |
Q4 (2027-28) |
Part B: Re-evaluations and standalone quantitative cumulative health risk assessment
Based on the currently available resources, the PMRA has established target publication dates for the proposed and final decisions of the re-evaluations that are in the review stage, as well as the next milestone target dates for the three standalone quantitative cumulative health risk assessments.
| Active ingredient name | Re-evaluation category | Target dateFootnote 1 |
|---|---|---|
| Proposed re-evaluation decisions (PRVD) – For consultation | ||
| 1 April 2025 to 31 March 2026 | ||
| Potassium bicarbonate | 2 | June 2025 |
| Sulphur | 2 | June 2025 |
| Ferric Sodium Ethylenediaminetetraacetic Acid | 3 | September 2025 |
| DEET plus related active toluamides | 1 | October 2025 |
| Iodosulfuron-methyl-sodium | 3 | October 2025 |
| Prohexadione calcium | 3 | November 2025 |
| Famoxadone | 1 | January 2026 |
| 1 April 2026 to 31 March 2027 | ||
Mecoprop cluster:
|
1 | Q1 2026-27 |
| Fenamidone | 1 | Q2 (2026-27) |
| Nonylphenoxypolyethoxyethanol | 3 | Q3 (2026-27) |
| Clothianidin general re-evaluation | 1 | Q3 (2026-27) |
| Cyazofamid | 3 | Q3 (2026-27) |
| Cyprodinil | 1 | Q3 (2026-27) |
Gibberellins cluster:
|
2 | Q3 (2026-27) |
| Thiamethoxam general re-evaluation | 1 | Q3 (2026-27) |
| Glufosinate ammonium | 1 | Q4 (2026-27) |
| Spinetoram | 1 | Q4 (2026-27) |
| Spinosad | 1 | Q4 (2026-27) |
Rodenticide Cluster:
|
1 | Q4 (2026-27) |
| 1 April 2027 to 31 March 2028 | ||
| Boscalid | 2 | Q1 (2027-28) |
| D-cis, trans-allethrin | 1 | Q1 (2027-28) |
| Ethofumesate | 1 | Q1 (2027-28) |
| (S)-Methoprene | 2 | Q1 (2027-28) |
| Acetamiprid | 1 | Q2 (2027-28) |
| Fluazinam | 1 | Q2 (2027-28) |
| Thiacloprid | 1 | Q2 (2027-28) |
| Methoxyfenozide | 1 | Q3 (2027-28) |
| Metribuzin | 1 | Q3 (2027-28) |
| Naled | 1 | Q3 (2027-28) |
| Phorate | 1 | Q3 (2027-28) |
| Picolinafen | 1 | Q3 (2027-28) |
| Prothioconazole | 1 | Q3 (2027-28) |
| 6-Benzylaminopurine | 1 | Q4 (2027-28) |
| Bensulide | 1 | Q4 (2027-28) |
| Tetrachlorvinphos | 1 | Q4 (2027-28) |
| Cumulative risk assessment | ||
| Cumulative Health Risk Assessment: N-Methyl Carbamates – Consultation for a proposed decision | 1 | Q1 (2027-28) |
| Cumulative Health Risk Assessment: Organophosphates – project planFootnote 2 | 1 | February 2026 |
| Cumulative Health Risk Assessment: Triazole – project planFootnote 2 | 1 | Q1 (2026-27) |
| Final re-evaluation decision (RVD) | Target dateFootnote 1 | |
| 1 April 2025 to 31 March 2026 | ||
| Methyl bromide | 1 | June 2025 |
| 3-Methyl-2-Cyclohexen-1-one | 3 | June 2025 |
| Abamectin | 1 | July 2025 |
| Streptomyces lydicus Strain WYEC108 | 3 | August 2025 |
| German Cockroach Extract | 3 | September 2025 |
Fatty Acid cluster:
|
2 | November 2025 |
Carbon dioxide cluster:
|
2 | November 2025 |
| Cellulose | 3 | November 2025 |
Silicon dioxide cluster:
|
3 | January 2026 |
| 1 April 2027 to 31 March 2028 | ||
| S-metolachlor and R-enantiomer | 1 | Q2 (2027-28) |
| Azoxystrobin | 1 | Q4 (2027-28) |
Part C: Re-evaluations – Early stage of re-evaluation process
The re-evaluations of the following active ingredients are in the early stage of the re-evaluation process. The PMRA will focus on the scoping reviews of these actives to determine the re-evaluation categories. Table 1 is the list of actives targeted first. The outcome of the scoping reviews will further inform prioritization of active ingredients for review phase, and the expected timelines for their public consultation will be included in the work plan to be published in spring 2026.
Part C: Table 1 List of actives (in alphabetical order) for which the scoping reviews are targeted first
Active ingredient name
- 10,10'-Oxybis(Phenoxarsine)
- 2-(Hydroxymethyl)-2-Nitro-1,3-Propanediol
- 2-Phenylphenol and Salts cluster:
- 2-Phenylphenol
- 2-Phenylphenol (present as Potassium Salt)
- 2-Phenylphenol (present as Sodium Salt)
- 2-(Thiocyanomethylthio)Benzothiazole
- Aminopyralid
- Aminopyralid
- Aminopyralid Triisopropanolamine Salt
- Aminopyralid Potassium Salt
- Ammonium Bromide
- Antimicrobial cluster
- 1,2-Benzisothiazolin-3-One
- 2-Methyl-4-Isothiazolin-3-One
- 4,5-Dichloro-2-N-Octyl-3(2H)-Isothiazolone
- 5-Chloro-2-methyl-4-isothiazolin-3-One
- Bacillus thuringiensis ssp. Tenebrionis
- Bacillus thuringiensis subspecies kurstaki (All Strains)
- Bacillus thuringiensis, Serotype H-14
- Beauveria bassiana Strain Hf23
- Bispyribac-Sodium
- Clonostachys rosea Strain J1446
- Coniothyrium minitans Strain Con/M/91-08
- Cyprosulfamide
- Fluvalinate-Tau
- Metarhizium brunneum Strain F52
- Methylene Bis(Thiocyanate)
- Mineral Oil
- N-Alkyl(25% C12, 60% C14, 15% C16)Dimethylbenzylammonium Chloride
- N-Dialkyl(5% C12, 60% C14, 30% C16, 5% C18)Methylbenzylammonium Chloride
- Ozone
- Pyrimethanil
- Pyroxsulam
- Tetrakishydroxymethyl Phosphonium Sulphate
Part C: Table 2 List of actives (in alphabetical order) in the early part of the re-evaluation process
Based on available resources, scoping reviews of actives in Table 2 will be targeted following the completion of the actives in Table 1 above, and Health Canada will provide an updated status of the following actives in the work plan to be published in spring 2026.
Active ingredient name
- 1,2-Dibromo-2,4-Dicyanobutane
- 2,4-D cluster:
- 2,4-D (present as Acid)
- 2,4-D (present as Amine Salts: Dimethylamine Salt, Diethanolamine Salt, or Other Amine Salts)
- 2,4-D (present as choline salt)
- 2,4-D (present as Low Volatile Esters)
- Acequinocyl
- Acifluorfen, present as Sodium Salt
- Alkyl Dimethyl Benzyl Ammonium Chloride Cluster (ADBAC):
- N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Chloride
- N-Alkyl (68% C12, 32% C14) Dimethyl Ethylbenzyl Ammonium Chloride
- N-Alkyl (5% C12, 60% C14, 30% C16, 5% C18) Dimethyl Benzyl Ammonium Chloride
- N-Alkyl (67% C12, 25% C14, 7% C16, 1% C18) Dimethyl Benzyl Ammonium Chloride
- Diisobutylphenoxyethoxyethyl Dimethyl Benzyl Ammonium Chloride
- N-Alkyl (40% C12, 50% C14, 10% C16) Dimethyl Benzyl Ammonium Saccharinate
- Antimicrobials cluster:
- 2,2-Dibromo-3-Nitrilopropionamide
- Bronopol
- Atrazine (plus related active Triazines)
- Bentazon cluster:
- Bentazon (present as Sodium Salt)
- Bentazone
- Bifenazate
- Bromacil (present in free form, as Dimethylamine Salt, or as Lithium Salt)
- Bromoxynil
- Carbendazim
- Carfentrazone-Ethyl
- Chlorpropham
- Chlorantraniliprole
- Clomazone
- Cloransulam-Methyl
- Daminozide
- Dicamba cluster:
- Dicamba (present as Acid)
- Dicamba (present as Acid, Ester, Salts)
- Dicamba (present as Diethanolamine Salt)
- Dicamba (present as Diglycoamine Salt)
- Dicamba (present as Dimethylamine Salt)
- Dicamba (present as Isopropylamine Salt)
- Dicamba (present as Monoethanolamine Salt)
- Dicamba (present as N-(2-Aminoethyl)-1,2-Ethanediamine Salt)
- Dicamba (present as N,N-Bis(3-Aminopropyl)Methylamine Salt)
- Dicamba (present as Potassium Salt)
- Dicamba (present as Sodium Salt)
- Dichlobenil
- Didecyl Dimethyl Ammonium Chloride Cluster (DDAC):
- Didecyl Dimethyl Ammonium Chloride – Other
- Didecyldimethylammonium (present as Carbonate and Bicarbonate Salts)
- Dioctyl Dimethyl Ammonium Chloride (present as Carbonate and Bicarbonate Salts)
- Octyl Decyl Dimethyl Ammonium Chloride
- Oxydiethylene Bis(Alkyl Dimethyl Ammonium Chloride)
- Diflubenzuron
- Diphenylamine
- Diuron
- Dioxaborinanes cluster:
- 2,2-(1-Methyltrimethylenedioxy)Bis-(4-Methyl1,3,2-Dioxaborinane)
- 2,2-Oxybis(4,4,6-Trimethyl-1,3,2-Dioxaborinane)
- Dodine
- Endothal cluster:
- Endothal
- Endothal, present as N,N-Dimethylalkylamine Salt
- EPTC (S-ethyl N,N-dipropylcarbamothioate)
- Etridiazole
- Fenbutatin Oxide
- Fish toxicants cluster:
- 4-Nitro-3-(trifluoromethyl) phenol sodium salt
- Niclosamide
- Flumioxazin
- Glutaraldehyde
- Imazapyr
- Ipconazole
- Maleic Hydrazide
- Mandipropamid
- MCPA cluster:
- MCPA (present as Acid)
- MCPA (present as Amine Salts: Diethanolamine, Dimethylamine, or Mixed Amines)
- MCPA (present as Esters)
- MCPA (present as Potassium Salt or as Sodium Salt)
- Mesotrione
- Metalaxyl cluster:
- Metalaxyl
- Metalaxyl-M and S-Isomer
- Metaldehyde
- Naphthalene Acetic Acid (present as Ethyl Ester, Sodium Salt, or as Ammonium Salt)
- Napropamide
- Novaluron
- Oxamyl
- Oxirane Derivatives - 50% Minimum
- Oxyfluorfen
- Pendimethalin
- Phosphonic acid cluster:
- Mono- and Di-Potassium Salt of Phosphorous Acid
- Mono- and Di-basic Sodium, Potassium, and Ammonium Phosphites
- Picloram cluster:
- Picloram (present as Potassium Salt)
- Picloram (present as Acid)
- Picloram (present as Amine Salts)
- Pinoxaden
- Prometryne Plus Related Active Triazines
- Pyraclostrobin
- Pyrasulfotole
- Rotenone
- Sodium Chlorite and Sodium Chlorate cluster (industrial uses):
- Sodium Chlorite
- Sodium Chlorate
- Spirodiclofen
- Spiromesifen
- Spirotetramat
- Streptomycin
- Sulfentrazone
- Sulfonyl Ureas cluster:
- Chlorsulfuron
- Ethametsulfuron-Methyl
- Metsulfuron-Methyl
- Nicosulfuron
- Rimsulfuron
- Thifensulfuron-Methyl
- Sulfuryl Fluoride
- Terbacil
- Thiencarbazone-Methyl
- Topramezone
- Triallate
- Triazinetrione cluster:
- Available Chlorine, present as Sodium Dichloro-S-Triazinetrione
- Available Chlorine, present as Trichloro-S-Triazinetrione
- Trichloro-S-Triazinetrione
- Available Chlorine present as Trichloro-S-Triazinetrione and Sodium Dichloro-S-Triazinetrione
- Triclopyr (present as Butoxyethyl Ester)
- Trifloxystrobin
Note: The following actives included in the REV2024-01 were discontinued following the initiations, and therefore their re-evaluations were closed:
- Sethoxydim (The discontinued products are being phased out and the last date of permitted use is 9 October 2027)
- Propylene glycol
- Pyrazon
Part D: Re-evaluation initiations between 1 April 2025 and 31 March 2030
Under the Pest Control Products Act, the PMRA is mandated to initiate re-evaluations for each registered pesticide on a 15-year cycle, based on the most recent major decision affecting the registration, including its initial registration (subsection 16(2) of the Pest Control Products Act). On a yearly basis, the PMRA updates the list of re-evaluations to be initiated in the next five fiscal years.
Part D: Table 1 Re-evaluation initiations between 1 April 2025 and 31 March 2027 (based on initiation date)
To further improve transparency for stakeholders and registrants, specific month of initiation of re-evaluation is included.
| Active ingredient name | Initiation dates |
|---|---|
| 1 April 2025 – 31 March 2026 | |
| Dimethenamid-P | April 2025 |
| Formetanate Hydrochloride | April 2025 |
| Hexazinone | April 2025 |
| Nosema (Paranosema) locustae Canning | April 2025 |
| Lime Sulphur Or Calcium Polysulphide | May 2025 |
| Beauveria bassiana Strain GHA | June 2025 |
| Carbathiin | June 2025 |
| Tribenuron-Methyl | June 2025 |
| Dithiopyr | September 2025 |
N-Decanol N-Octanol |
September 2025 |
| Phenmedipham | September 2025 |
| Propyzamide | September 2025 |
| Trifluralin | September 2025 |
| Verticillium albo-atrum, Isolate Wcs850 | October 2025 |
Alkyl trimethylenediamines cluster:
|
December 2025 |
| Saflufenacil | February 2026 |
| Chlormequat Chloride | March 2026 |
| Simazine Plus Related Active Triazines | March 2026 |
| 1 April 2026 – 31 March 2027 | |
| Diquat | April 2026 |
| Iron (present as FeHEDTA) | April 2026 |
| Tembotrione | April 2026 |
Animal repellent cluster:
|
May 2026 |
| Dichlorprop P-Isomer (Present as 2-Ethylhexyl Ester) | June 2026 |
| Naphthlene | June 2026 |
| Pseudomonas syringae – Strain Esc-10 | July 2026 |
Lactobacillus casei Strain LPT-111 Lactobacillus rhamnosus Strain LPT-21 Lactococcus lactis ssp. cremoris Strain M11/CSL Lactococcus lactis ssp. lactis Strain Ll64/CSL Lactococcus lactis ssp. lactis Strain Ll102/CSL Lactic Acid Citric Acid |
July 2026 |
| Mesosulfuron-Methyl | August 2026 |
| Metrafenone | September 2026 |
| Paradichlorobenzene | September 2026 |
| Tefluthrin | September 2026 |
| Thymol | October 2026 |
| Imazethapyr | October 2026 |
Trimethoxysilyl quats cluster:
|
October 2026 |
| Diodofon | October 2026 |
| Hexahydro-1,3,5-Tris(2-Hydroxyethyl)-S-Triazine | October 2026 |
| Oxalic Acid Dihydrate | November 2026 |
| D-Limonene | November 2026 |
| Flonicamid | December 2026 |
| Saponins Of Chenopodium Quinoa | December 2026 |
| 1,4-Dimethylnaphthalene | January 2027 |
| Tralkoxydim | January 2027 |
| Iodocarb – Other | March 2027 |
| Thiabendazole | March 2027 |
Note: The following actives included in the REV2024-01 for initiation in the fiscal year of 2025-26 will not be initiated:
- Imazamethabenz-Methyl and R-(-)-1-Octen-3-ol will not be initiated as there are no associated registered end-use products.
- Oxycarboxin, diazinon, bifenthrin, desmedipham and Pseudomonas fluorescens A506 will not be initiated as these products were discontinued.
Note: The following active included in the REV2024-01, initiated in the fiscal year of 2025-26 was discontinued following the initiation, and therefore its re-evaluation was closed:
Nosema (Paranosema) locustae Canning
Note: The following actives included in the REV2024-01 for initiation in the fiscal year 2026-27 will not be initiated:
- Dichlorprop-P and dichlorprop-P (present as dimethylamine salt) will not be initiated as there are no associated end-use products currently registered in Canada.
- Sodium fluoride, butoxypolypropylene glycol, and acibenzolar-S-methyl will not be initiated as all of associated products were discontinued.
Part D: Table 2 Future re-evaluation initiations between 1 April 2027 and 31 March 2030
The initiations for the active ingredients in the following table will be updated annually.
1 April 2027 to 31 March 2028
Heavy duty wood preservative cluster:
- Arsenic Acid
- Chromic Acid
- Creosote
- Zinc (present as Zinc Oxide)
- Copper (present as Basic Copper Carbonate)
Hydantoins cluster:
- Available Bromine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins
- Available Chlorine present as 1,3-Dichloro-5,5-Dimethylhydantoin and 1,3-Dichloro-5-Ethyl-5-Methylhydantoin
- Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin and Related Hydantoins
- Available Chlorine present as 1-Bromo-3-Chloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5,5-Dimethylhydantoin, 1,3-Dichloro-5-Ethyl-5-Methylhydantoin and Related Hydantoins
Bacillus firmus I-1582
Clopyralid
Copper (present as Copper 8-Quinolinolate)
Copper (present as Copper Naphthenate)
Zinc as Elemental (present as Zinc Naphthenate)
Cydia pomonella granulovirus (Strain M)
Extract of Reynoutria sachalinensis
Fluopicolide
Formaldehyde
Paraformaldehyde
Icaridin
Indaziflam
Metofluthrin
Oriental Mustard Seed Meal
Paecilomyces fumosoroseus Strain FE 9901
Penflufen
Penthiopyrad
Phoma macrostoma
Propiconazole
Trichoderma asperellum Strain T34
1 April 2028 to 31 March 2029
Ametoctradin
Ammonia (present as Ammonium Sulfate)
Aureobasidium pullulans cluster:
- Aureobasidium pullulans Strain DSM 14940 and DSM 14941
- Aureobasidium pullulans Strain DSM 14940
- Aureobasidium pullulans Strain DSM 14941
Bacillus subtilis var. amyloliquefaciens Strain FZB24
Clavibacter michiganesis spp. michiganensis Bacteriophage
Cloquintocet-Mexyl
Denatonium Benzoate
Ethalfluralin
Fenoxaprop-P-Ethyl
Fluazifop-P-Butyl and S-Isomer
Fluopyram
Fluoxastrobin
Fluxapyroxad
Kasugamycin (Present as Hydrochloride Hydrate)
Malathion
MCPB (Present as Soduim Salt)
Mint oil cluster:
- Cornmint Oil
- Methyl Salicylate
Octadecadien-1-ol cluster:
- (E,Z)-2,13-Octadecadien-1-yl Acetate
- (Z,Z)-3,13-Octadecadien-1-ol
- (E,Z)-3,13-Octadecadien-1-ol
Picoxystrobin
Poly[Oxyethylene(Dimethyliminio)Ethylene (Dimethyliminio)Ethylene Dichloride]
Potassium Dimethyldithiocarbamate Salts
Pseudomonas fluorescens Strain CL145A
Pyroxasulfone
Sedaxane
Sulfoxaflor
Tetraconazole
Trichoderma virens Strain G-41
1 April 2029 to 31 March 2030
3-Decen-2-One
Bacillus subtilis Strain GB03
Chlorfenapyr
Cyantraniliprole
Ethylene Oxide
Garlic Juice
Garlic Powder
Halosulfuron (Present as Methyl Ester)
Myclobutanil
P-Menthane-3,8-Diol And Related Oil Of Lemon Eucalyptus Compounds
Streptomyces acidiscabies Strain Rl-110t Cells And Spent Fermentation Media
Tea Tree Oil
Tributyl Tetradecyl Phosphonium Chloride
Page details
- Date modified: